Genomed Spólka Akcyjna Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Genomed Spólka Akcyjna's earnings have been declining at an average annual rate of -9.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 3.4% per year. Genomed Spólka Akcyjna's return on equity is 6.4%, and it has net margins of 2.7%.
Belangrijke informatie
-9.2%
Groei van de winst
-9.2%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 56.3% |
Inkomstengroei | 3.4% |
Rendement op eigen vermogen | 6.4% |
Nettomarge | 2.7% |
Volgende winstupdate | 13 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Genomed Spólka Akcyjna geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 22 | 1 | 12 | 0 |
31 Mar 24 | 22 | 1 | 11 | 0 |
31 Dec 23 | 22 | 1 | 11 | 0 |
30 Sep 23 | 21 | 0 | 11 | 0 |
30 Jun 23 | 21 | 0 | 11 | 0 |
31 Mar 23 | 21 | 0 | 11 | 0 |
31 Dec 22 | 20 | 0 | 10 | 0 |
30 Sep 22 | 20 | 1 | 10 | 0 |
30 Jun 22 | 20 | 1 | 11 | 0 |
31 Mar 22 | 20 | 2 | 10 | 0 |
31 Dec 21 | 20 | 1 | 10 | 0 |
30 Sep 21 | 20 | 1 | 10 | 0 |
30 Jun 21 | 20 | 1 | 10 | 0 |
31 Mar 21 | 19 | 0 | 10 | 0 |
31 Dec 20 | 19 | 0 | 10 | 0 |
30 Sep 20 | 19 | 0 | 10 | 0 |
30 Jun 20 | 19 | 1 | 10 | 0 |
31 Mar 20 | 20 | 1 | 11 | 0 |
31 Dec 19 | 20 | 1 | 11 | 0 |
30 Sep 19 | 19 | 1 | 11 | 0 |
30 Jun 19 | 19 | 1 | 11 | 0 |
31 Mar 19 | 18 | 1 | 10 | 0 |
31 Dec 18 | 19 | 1 | 10 | 0 |
30 Sep 18 | 18 | 2 | 9 | 0 |
30 Jun 18 | 17 | 2 | 8 | 0 |
31 Mar 18 | 17 | 2 | 8 | 0 |
31 Dec 17 | 16 | 2 | 8 | 0 |
30 Sep 17 | 16 | 1 | 9 | 0 |
30 Jun 17 | 16 | 1 | 9 | 0 |
31 Mar 17 | 15 | 0 | 9 | 0 |
31 Dec 16 | 14 | 0 | 9 | 0 |
30 Sep 16 | 14 | 1 | 8 | 0 |
30 Jun 16 | 12 | 1 | 7 | 0 |
31 Mar 16 | 11 | 0 | 7 | 0 |
31 Dec 15 | 10 | 0 | 7 | 0 |
30 Sep 15 | 9 | 0 | 7 | 0 |
30 Jun 15 | 8 | 0 | 7 | 0 |
31 Mar 15 | 8 | 0 | 6 | 0 |
31 Dec 14 | 7 | 0 | 6 | 0 |
30 Sep 14 | 6 | 0 | 6 | 0 |
30 Jun 14 | 6 | 0 | 5 | 0 |
31 Mar 14 | 5 | 0 | 5 | 0 |
31 Dec 13 | 5 | 0 | 4 | 0 |
Kwaliteitswinsten: GEN has high quality earnings.
Groeiende winstmarge: GEN's current net profit margins (2.7%) are higher than last year (1.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: GEN's earnings have declined by 9.2% per year over the past 5 years.
Versnelling van de groei: GEN's earnings growth over the past year (113.5%) exceeds its 5-year average (-9.2% per year).
Winst versus industrie: GEN earnings growth over the past year (113.5%) exceeded the Biotechs industry -20.8%.
Rendement op eigen vermogen
Hoge ROE: GEN's Return on Equity (6.4%) is considered low.